BBA
NERV icon

Baker Bros. Advisors’s Minerva Neurosciences NERV Stock Holding History

Baker Bros. Advisors’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-86,066
Closed -$4.14M – 117
2020
Q1 		$4.14M Buy
+86,066
New +$5.19M 0.03% 71
2017
Q1 		– Sell
-32,351
Closed -$3.04M – 126
2016
Q4 		$3.04M Hold
32,351
– – 0.03% 74
2016
Q3 		$3.65M Sell
32,351
-31,200
-49% -$3.03M 0.03% 73
2016
Q2 		$5.19M Buy
+63,551
New +$4.04M 0.05% 73

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baker Bros. Advisors's NERV Position: Q2 2020 in Review

Baker Bros. Advisors sold out of Minerva Neurosciences (NERV) in Q2 2020, closing a stake of 86,066 shares — an estimated $4.14M sold.

Baker Bros. Advisors first reported a position in NERV in Q2 2016 and held it in 4 quarters. The position peaked at $5.19M in Q2 2016. 80 funds tracked by Wall St. Rank hold NERV as of Q2 2020.

  • Baker Bros. Advisors reported no remaining Minerva Neurosciences position as of Q2 2020 after selling out during the quarter.
  • Baker Bros. Advisors sold 86,066 Minerva Neurosciences shares in Q2 2020, an estimated $4.14M.
  • Baker Bros. Advisors first reported a position in Minerva Neurosciences in Q2 2016 and held it in 4 quarters.
  • Baker Bros. Advisors's Minerva Neurosciences position peaked at $5.19M in Q2 2016.
  • 80 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2020.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.